lished a platform for truly interdisciplinary debates and open exchange of ideas. It was decided that the workshops will be held annually under the alternative leadership of each society. As a result of the 2013 workshop, new, up-dated and revised 'Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery' were created by an expert panel of EASO and IFSO-EC members. The guidelines are presented in this issue of OBESITY FACTS to all readers. Type 2 diabetes mellitus is one of the most prominent fields where the medico-surgical treatment efforts are gradually melting in a pot which is still hot. Several decades ago the U.K. Prospective Diabetes Study (UKPDS) was mainly designed to determine whether improved blood glucose control in type 2 diabetes will prevent diabetes complications. It really worked out well for microvascular complications. However, a UKPDS overview of 6 years' therapy of type 2 diabetes reported that progressively increasing hyperglycaemia, which is associated with decreasing beta cell function, was a marked feature irrespective of the therapy used (conventional therapy-diet only vs. intensive medical therapy). Thus, with these findings the clinicians came to the conclusion that type 2 diabetes is a progressive disease, and the researchers have plunged into the pursuit of discovering novel therapies either halting or reversing this progression ever since [1] . Recently a metabolic sub-study of the Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) trial has compared bariatric surgery with intensive medical therapy in obese patients with type 2 diabetes. The 2-year results demonstrated a significant improvement in beta cell function in patients followed up in the surgical arm of the study [2] . We find the journey from the UKPDS to the STAMPEDE trial quite fascinating but are cautiously waiting for more, robust evidence from future randomised clinical trials (RCTs).
Diabetes remission actually means resolution of glycaemic parameters. To put it another way it is reaching the targets and staying there so that complications are avoided or they regress. It seems that talking about a cure is too early. Post-bariatric surgery diabetes remission rates were considerably high in previous studies. There were inter-study variations regarding the definition for remission. Recent RCTs have adopted the ADA Consensus criteria for diabetes remission, hence bringing in a standard end point [3] .
Although the outcome studies concerning the diabetic complications after metabolic surgery are scarce, an un-blinded, case-controlled trial with 10-year follow up demonstrated that renal and cardiovascular complications were dramatically reduced in the surgical arm, indicating long-term benefits of bilio-pancreatic diversion on diabetic complications in the case of morbid obesity with decompensated diabetes [4] . The review of the key results from the Swedish Obese Subjects (SOS) trial showed that, compared to conventional therapy, bariatric surgery was associated with a long-term reduction in overall mortality and decreased incidence of diabetes, myocardial infarction, stroke and cancer [5] .
EASO and IFSO-EC are convinced that the only way forward is based on the paradigm that physicians and surgeons must work in collaboration and follow the joint guidelines produced based on current scientific evidence in cooperation of IFSO-EC and EASO whose members have been successfully working together in accordance with a perfect physician-surgeon team spirit.
